open access
Possibilities in the application of solid lipid nanoparticles in combination with 5-fluorouracil to overcome the drugresistance of non-small cell lung cancer cell line A549
, 2, 2, 2, 2, 12, 12
Affiliations- Department of Histology and Embryology, Faculty of Medicine, Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń, 24 Karłowicza St., 85-092 Bydgoszcz, Poland
- Students research group of Cell Biology and Ultrastructure at Department of Histology and Embryology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland., 24 Karłowicza St., 85-092 Bydgoszcz, Poland
open access
Abstract
Introduction: Multidrug resistance of non-small cell lung cancer cells is associated with a high percentage
of therapeutic failures. The aim of this study was to assess the ability of solid lipid nanoparticles as a
transporter of the conventionally used cytostatic (5-fluorouracil) to overcome the resistance of A549 cells.
Material and methods: MTT assay was used to assess the differences in viability of cells treated with
5-fluorouracil alone or in combination with different types of solid lipid nanoparticles. Type of cell death
and distribution of cell cycle phases were evaluated using flow cytometry.
Results: The use of nanoparticles as a 5-fluorouracil transporter reduced the viability of A549 cells to a
greater extent than the cytostatic alone. This was mainly due to the increase in apoptosis, but also necrosis
and cell cycle arrest.
Conclusion: Our results indicate the great potential of nanotechnology in the treatment of non-small cell
lung cancer. By using nanoparticles, it is possible to sensitise tumour cells to cytostatics to which they
are normally resistant. In addition, literature data confirm the safety of solid lipid nanoparticle application.
Abstract
Introduction: Multidrug resistance of non-small cell lung cancer cells is associated with a high percentage
of therapeutic failures. The aim of this study was to assess the ability of solid lipid nanoparticles as a
transporter of the conventionally used cytostatic (5-fluorouracil) to overcome the resistance of A549 cells.
Material and methods: MTT assay was used to assess the differences in viability of cells treated with
5-fluorouracil alone or in combination with different types of solid lipid nanoparticles. Type of cell death
and distribution of cell cycle phases were evaluated using flow cytometry.
Results: The use of nanoparticles as a 5-fluorouracil transporter reduced the viability of A549 cells to a
greater extent than the cytostatic alone. This was mainly due to the increase in apoptosis, but also necrosis
and cell cycle arrest.
Conclusion: Our results indicate the great potential of nanotechnology in the treatment of non-small cell
lung cancer. By using nanoparticles, it is possible to sensitise tumour cells to cytostatics to which they
are normally resistant. In addition, literature data confirm the safety of solid lipid nanoparticle application.
Keywords
A549, solid lipid nanoparticles, 5-fluorouracil, drug-resistance, nanotechnology
About this articleTitle
Possibilities in the application of solid lipid nanoparticles in combination with 5-fluorouracil to overcome the drugresistance of non-small cell lung cancer cell line A549
Journal
Issue
Article type
Original article
Pages
1-8
Published online
2019-12-19
Page views
634
Article views/downloads
894
DOI
Bibliographic record
Medical Research Journal 2020;5(1):1-8.
Keywords
A549
solid lipid nanoparticles
5-fluorouracil
drug-resistance
nanotechnology
Authors
Wioletta Zielińska
Agnieszka Nawrocka
Maciej Rydzkowski
Anna Kokocha
Karolina Matulewicz
Marta Hałas-Wiśniewska
Magdalena Izdebska
References (25)- Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5): 584–594.
- Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb). 2014; 6(1): 9–26.
- Allegra A, Penna G, Alonci A, et al. Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem. 2011; 11(7): 669–686.
- Zheng G, Zheng M, Yang B, et al. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother. 2019; 116: 109006.
- Chowdhury P, Nagesh PKB, Hatami E, et al. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Colloid Interface Sci. 2019; 535: 133–148.
- Yang C, Uertz J, Chithrani DB. Colloidal Gold-Mediated Delivery of Bleomycin for Improved Outcome in Chemotherapy. Nanomaterials (Basel). 2016; 6(3).
- Clemente N, Ferrara B, Gigliotti CL, et al. Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. Int J Mol Sci. 2018; 19(2).
- Shi S, Zhou M, Li X, et al. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. J Control Release. 2016; 235: 1–13.
- Ying XY, Cui D, Yu L, et al. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydrate Polymers. 2011; 84(4): 1357–1364.
- Kucuk O, Shevrin DH, Pandya KJ, et al. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000; 23(4): 371–375.
- Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014; 34(4): 1531–1535.
- Jung H, Wang SY, Yang IW, et al. Detection and treatment of mycoplasma contamination in cultured cells. Chang Gung Med J. 2003; 26(4): 250–258.
- Chou TC, Martin N. CompuSyn for drug combinations: PC Software and User's Guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. Paramus (NJ): ComboSyn. ; 2005.
- Wu DW, Huang CC, Chang SW, et al. Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ. 2015; 22(5): 779–789.
- Akagi H, Higuchi H, Sumimoto H, et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 2013; 16(1): 100–110.
- Jover R, Nguyen TP, Pérez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011; 140(4): 1174–1181.
- Gu W, Fang FF, Li B, et al. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. Asian Pac J Cancer Prev. 2012; 13(9): 4807–4814.
- Kawahara A, Akagi Y, Hattori S, et al. Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. J Clin Pathol. 2009; 62(4): 364–369.
- Zhang N, Yin Y, Xu SJ, et al. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008; 13(8): 1551–1569.
- Du B, Yan Y, Li Y, et al. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. Pharm Dev Technol. 2010; 15(4): 346–353.
- Khallaf RA, Salem HF, Abdelbary A. 5-Fluorouracil shell-enriched solid lipid nanoparticles (SLN) for effective skin carcinoma treatment. Drug Deliv. 2016; 23(9): 3452–3460.
- Thukral DK, Dumoga S, Mishra AK. Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery. Curr Drug Deliv. 2014; 11(6): 771–791.
- Pfeffer CM, Singh ATK. Apoptosis: A Target for Anticancer Therapy. Int J Mol Sci. 2018; 19(2).
- Li Q, Huang C, Liu L, et al. Effect of Surface Coating of Gold Nanoparticles on Cytotoxicity and Cell Cycle Progression. Nanomaterials (Basel). 2018; 8(12).
- Yuan Q, Han J, Cong W, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomedicine. 2014; 9: 4829–4846.